Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation of Revenue [Line Items]
Total revenues	$ 14,967	$ 12,319	$ 29,637	$ 27,901
Americas [Member]
Disaggregation of Revenue [Line Items]
Total revenues	6,906	4,076	12,131	6,913
EMEA [Member]
Disaggregation of Revenue [Line Items]
Total revenues	3,314	4,741	9,285	12,466
APAC [Member]
Disaggregation of Revenue [Line Items]
Total revenues	4,747	3,502	8,221	8,522
Product Sales [Member]
Disaggregation of Revenue [Line Items]
Total revenues	4,504	6,249	9,604	14,236
Research and Development Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenues	10,463	6,070	20,033	13,665
Performance Enzymes [Member]
Disaggregation of Revenue [Line Items]
Total revenues	7,506	10,589	18,379	20,676
Performance Enzymes [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Total revenues	1,173	4,076	4,171	6,913
Performance Enzymes [Member] | EMEA [Member]
Disaggregation of Revenue [Line Items]
Total revenues	1,586	3,011	5,987	5,241
Performance Enzymes [Member] | APAC [Member]
Disaggregation of Revenue [Line Items]
Total revenues	4,747	3,502	8,221	8,522
Performance Enzymes [Member] | Product Sales [Member]
Disaggregation of Revenue [Line Items]
Total revenues	4,504	6,249	9,604	14,236
Performance Enzymes [Member] | Research and Development Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenues	3,002	4,340	8,775	6,440
Novel Biotherapeutics [Member]
Disaggregation of Revenue [Line Items]
Total revenues	7,461	1,730	11,258	7,225
Novel Biotherapeutics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Total revenues	5,733	0	7,960	0
Novel Biotherapeutics [Member] | EMEA [Member]
Disaggregation of Revenue [Line Items]
Total revenues	1,728	1,730	3,298	7,225
Novel Biotherapeutics [Member] | APAC [Member]
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0	0
Novel Biotherapeutics [Member] | Product Sales [Member]
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0	0
Novel Biotherapeutics [Member] | Research and Development Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenues	$ 7,461	$ 1,730	$ 11,258	$ 7,225